

Automating Breast Cancer Biopsies for Accurate Diagnosis



Team: Neha Chellu¹, Youran (Peggy) Li⁴, Moonhyung (Bruce) Lee¹, Ishir Sharma^{1,2}, Sangmita Singh⁵, Hassan Farah¹, Derek Minn¹, Shreya Tiwari¹ **Project Mentors:** Dr. Elizabeth A. Logsdon^{1,2}, Dr. Youseph Yazdi^{1,2}, Dr. Emily Ambinder³

¹Department of Biomedical Engineering, JHU, ²Center for Bioengineering Innovation and Design, JHU, ³Department of Radiology and Radiological Science, Johns Hopkins Medicine, Baltimore, MD, USA, ⁴Department of Bioengineering, Stanford University, Stanford, CA, USA, ⁵Department of Bioengineering, Massachusetts Institute of Technology, Boston, MA, USA


Introduction and Background




231,000 women in Sub-Saharan Africa (SSA) are at risk of developing breast cancer annually



In SSA, 1 in 2 women with breast cancer will die of their condition, largely due to late diagnosis






False-Negative Rate of FNA for cancers

Rate of FNA for cancers

20-62.6%

enable an accurate diagnosis

Inconclusive




Key Objectives

Goal 1: Improve the cellularity of FNA samples to enable representative diagnostic samples*
Goal 2: Simplify the procedure to expand accessibility at Tier 2 Healthcare centers
Goal 3: Expand the use of FNA to accurately diagnose various cancers and infectious diseases

*Representative diagnostic samples = Containing cells representative of the target lesion microenvironment that accurately reflect the health condition of the patient.

Our Solution



Problem Impact

Up to 11.3 months
of treatment delay


Tumor size doubles
every six months for
invasive breast cancer

>170 million people
in SSA live 2+ hours from
the nearest Tier 3/Tier 4
hospital


Methods

- Preliminary testing of multiple agitational motions on a goat liver model identified that a combination of linear and rotational motion is the most effective mode of agitation for increasing sample cellularity.
- Validation testing of combined linear-rotational motion showed higher sample cellularity with prototype compared to manual FNA.
- Cell quantification was performed using ImageJ Cell Counter (Fiji, v2.9.0).

Results



Comparison of Aspirate Cell Concentration between Manual and Device-Assisted FNA (n=10)



Acknowledgements

We would like to thank our committee members: **Dr. Yekosani Mitala, Dr. Robert Lukande, Dr. Dan Wamala, Dr. Nixon Niyonzima, and Dr. Amy Ly** for their clinical insights, as well as **Dr. Robert Ssekitoleko, Dr. William Wasswa, and Mr. George Coles** for their technical feedback. We also appreciate the **Johns Hopkins Biomedical Engineering** department and Faculty and Staff of the Design Team program for their support of our project.